Zaltrap® (ziv-aflibercept)

BL 125418

Zaltrap® (ziv-aflibercept)

BL 125418

U.S. License Holder:

Sanofi Aventis US

Date of License:

August-03-2012

Last Update:

Nov-15-2024

approved_indications FDA-Approved Indications

ZALTRAP (ziv-aflibercept), a vascular endothelial growth factor inhibitor, in combination with fluorouracil, leucovorin, irinotecan (FOLFIRI), is indicated for the treatment of patients with metastatic colorectal cancer that is resistant to or has progressed following an oxaliplatin-containing regimen.

approved_indications U.S. Patent Litigations

PACER

Case No(s):

1:18-cv-02434 (S.D.N.Y.)

U.S. Patent Nos.
5,688,688 (Vector for Expression of a Polypeptide in a Mammalian Cell)

Plaintiffs
Novartis Vaccines and Diagnostics, Inc.; Novartis Pharma AG; Grifols Worldwide Operations Limited

Defendants
Regeneron Pharmaceuticals, Inc.

Status
Stipulated Judgment of Non-Infringement and Order of Dismissal

BPCIA
N

7:11-cv-09463 (S.D.N.Y.)

U.S. Patent Nos.
6,100,071 (Receptors as Novel Inhibitors of Vascular Endothelial Growth Factor Activity and Processes for their Production) 6,383,486 (Inhibitors of Vascular Endothelial Growth Factor Activity, their Uses and Processes for their Production) 6,897,294 (Inhibitors of Vascular Endothelial Growth Factor Activity, their Uses and Processes for their Production) 7,771,721 (Methods for using Chimeric Vascular Endothelial Growth Factor Receptor Proteins)

Plaintiffs
Genentech, Inc.

Defendants
Regeneron Pharmaceuticals, Inc.; Sanofi-Aventis US, Inc.; Sanofi-Aventis US LLC; Sanofi; Sanofi-Aventis Amerique Du Nord SNC

Status
Dismissed

BPCIA
N

Related News

Venable’s BiologicsHQ Monthly Injection – September 2019
April Breyer Menon Corinne E. Atton Robert S. Schwartz, Ph.D.
October 8, 2019
Venable’s BiologicsHQ Monthly Injection – April 2019
April Breyer Menon Corinne E. Atton Robert S. Schwartz, Ph.D.
May 7, 2019
Venable’s BiologicsHQ Monthly Injection – March 2018
April M. Breyer Menon Corinne E. Atton Robert S. Schwartz, Ph.D.
April 6, 2018

Methodology

Information contained in the Venable BiologicsHQ database relates to FDA-approved drug products listed in the CDER Purple Book or on the FDA website (www.fda.gov). Information relating to FDA licensed products, FDA-approved indications, and aBLA and 505(b)(2) applications is obtained from public sources including the U.S. FDA website (www.fda.gov). Information relating to litigations is given only for cases active from January 31, 2010 onward. Information relating to foreign biosimilar / biologics follow-on products approved in Australia, Canada, the E.U., Japan and South Korea is from public sources. Statistics graphics are compiled from information contained in the Venable BiologicsHQ database.

Disclaimer

The individuals who maintain this site work for Venable LLP. The information, comments and links posted on this site do not constitute legal advice. No attorney-client relationship has been or will be formed by any communication(s) to, from or with the site and/or the author. For legal advice, contact an attorney at Venable LLP or an attorney actively practicing in your jurisdiction. Do not send any confidential or privileged information to the author; neither Venable LLP nor the author will assume any liability or responsibility for it. If you send any information, documents or materials to the site, you give permission for the author to include them on or in the site. No information, documents or materials you send to the site will be considered confidential or privileged by Venable LLP or its lawyers. Also, no such information, documents or materials will be returned to you. All decisions relating to the content belong to the author.

Subscribe for Future Updates

    captcha